Gilead Sciences, Inc. GILD reported better-than-expected fourth-quarter results and provided an upbeat guidance for 2025.
Biogen stock took a hit Wednesday after the biotech company issued light guidance for 2025 despite beating most fourth-quarter expectations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback